Executive Summary
The plaintiff filed a suit seeking substantial damages against the defendant, alleging wrongful interference with business due to the defendant's patented product. The defendant sought rejection of the plaint under Order VII Rule 11(d) of the CPC, arguing lack of cause of action and correlation between the patent and the alleged business loss. The Court dismissed the application, finding that the plaint, when read as a whole, disclosed sufficient cause of action.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Calcutta High Court. Understanding the court's reasoning in Baynee Industries vs Rajiv Rosha is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Kanishk SinhavsState of West Bengal
The petitioner, a patentee, challenged actions of the State regarding e-rickshaws, asserting that defendants were infringing his patent on echo friendly vehicles. The court affirmed the petitioner's status as a patent holder and held that any license granted by the State in violation of the existing injunction would be void ab initio.
LG Electronics IncvsShenzhen Transsion Holdings Co Ltd & Ors
LG Electronics Inc filed a suit against Shenzhen Transsion Holdings Co Ltd & Ors seeking restraining orders for infringing its Standard Essential Patents (SEPs) related to 4G and 5G cellular standards. The court passed several interim orders allowing the plaintiff various applications, including filing confidential documents and adding claims for infringement of additional patents.
Zydus Healthcare LimitedvsFlipkart Internet Pvt Ltd & Ors.
The Delhi High Court addressed concerns raised by Zydus Healthcare regarding counterfeit goods sold on Flipkart. While acknowledging that e-commerce platforms have mechanisms in place, the court highlighted critical procedural flaws, particularly concerning seller onboarding, GST misuse, and product identification (FSN). The judgment mandates Flipkart to investigate these issues, provide specific documentation like bank details, and implement technical solutions to prevent genuine sellers from being unfairly de-listed.
Bristol-Myers Squibb Holdings Ireland Unlimited CompanyvsCipla Limited
The dispute between Bristol-Myers Squibb Holdings Ireland and Cipla Limited regarding the commercialization of Apixaban was amicably settled. The defendant confirmed that it did not commercialize the drug under the brand name APIGY until after the expiry of the suit patent.
Novartis Ag & AnrvsController General Of Patents, Designs, Trademarks And Geographical Indications & Ors.
Petitioners filed a writ petition seeking directions to expedite the consideration of their Indian Patent Application No. 1014/DELNP/2011, which had been pending for over 15 years despite multiple pre-grant oppositions being filed. The Court noted the unacceptable delay and directed the Respondents to decide the application and all related oppositions as expeditiously as possible within four months.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.